Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

Radiation therapy and overall survival in male breast cancer: a multicenter analysis of 302 patients.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Radiation therapy and overall survival in male breast cancer: a multicenter analysis of 302 patients.
Συγγραφείς: Colciago RR; Medicine and Surgery Department, University of Milan Bicocca, 20126, Milan, Italy. Riccardoraycolciago@gmail.com., Franco P; Department of Translational Medicine (DIMET), University of Eastern Piedmont, Novara, Italy.; Department of Radiation Oncology, 'Maggiore Della Carità' University Hospital, 28100, Novara, Italy., Giandini C; Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori Di Milano, 20133, Milan, Italy., Carnevale MG; Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori Di Milano, 20133, Milan, Italy., Di Cosimo S; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133, Milan, Italy., Minicozzi P; Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133, Milan, Italy., Manitto R; Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133, Milan, Italy., Ferrara E; Department of Radiation Oncology, 'Maggiore Della Carità' University Hospital, 28100, Novara, Italy., Fozza A; Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Coco A; Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Spoto R; Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, 20089, RozzanoMilan, Italy., Dominici L; Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, 20089, RozzanoMilan, Italy., Marino L; Servizio Di Radioterapia, Humanitas Istituto Clinico Catanese, Misterbianco, CT, Italy., Lucidi S; Radiation Oncology, APSS, Trento, Italy., De Rose F; Radiation Oncology, APSS, Trento, Italy., Bonzano E; Radiation Oncology Department, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy., Prisco A; Department of Radiation Oncology, University Hospital of Udine, ASUFC, 33100, Udine, Italy., Meduri B; Protontherapy Department, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy., Bertini N; Radiation Oncology & Breast Unit, Florence University Hospital, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Meattini I; Radiation Oncology & Breast Unit, Florence University Hospital, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy.; Department of Radiation Oncology (MAASTRO), GROW Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Verderio P; Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133, Milan, Italy., De Santis MC; Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori Di Milano, 20133, Milan, Italy.
Πηγή: La Radiologia medica [Radiol Med] 2026 Oct; Vol. 131 (10), pp. 1935-1948. Date of Electronic Publication: 2026 Sep 28.
Τύπος έκδοσης: Journal Article; Multicenter Study
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Springer Milan Country of Publication: Italy NLM ID: 0177625 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1826-6983 (Electronic) Linking ISSN: 00338362 NLM ISO Abbreviation: Radiol Med Subsets: MEDLINE
Imprint Name(s): Publication: Milan : Springer Milan
Original Publication: Torino [etc.] Minerva medica.
Ιατρικοί όροι (MeSH): Breast Neoplasms, Male*/radiotherapy , Breast Neoplasms, Male*/mortality , Breast Neoplasms, Male*/pathology, Italy/epidemiology ; Humans ; Male ; Retrospective Studies ; Radiotherapy, Adjuvant ; Aged ; Neoplasm Staging ; Middle Aged ; Disease-Free Survival ; Mastectomy ; Prognosis ; Survival Rate ; Aged, 80 and over ; Chemotherapy, Adjuvant
Περίληψη: Aim: This multicenter study aimed to assess the efficacy and the prognostic role of adjuvant radiation therapy and other factors in a cohort of male breast cancer patients (MaBC) treated in 10 Italian centers within the Clinical Oncology Breast Cancer Group.
Methods: This retrospective study included patients diagnosed with MaBC between 2005 and 2023. Demographic, clinical, tumor, and treatment data were retrieved from medical records. Information on treatment-related acute and late adverse events was also collected. Disease-free survival (DFS) was calculated from surgery to recurrence or last follow-up visit, overall survival (OS) from diagnosis to death or last follow-up visit.
Results: Overall, 302 patients were included (median age 69). Most were diagnosed with stage I-IIIa (75%; vs 25% stage IIIb-IV), invasive ductal carcinoma (88%) and luminal-like tumors (88%). Nearly all patients underwent mastectomy (96%), 31% received adjuvant chemotherapy, 83% endocrine therapy (mainly tamoxifen), and 33% radiation therapy. At a median follow-up of 79 months, DFS and OS were significantly associated, among others, with stage (p < 0.05). In stage IIIb-IV patients, omission of radiation therapy was associated with higher recurrence risk (hazard ratio, HR = 18.8, p < 0.001) and worse OS (HR = 6.45, p < 0.001). Acute radiation therapy-related adverse events occurred in 28% of patients, mostly graded 1-2, but no severe late toxicity was observed.
Conclusions: This large retrospective cohort study showed that MaBC patients treated with multi-modality therapies achieved favorable outcomes. Specifically, radiation therapy significantly improved survival in advanced stages with low incidence of late adverse events further supporting its role in daily clinical practice.
(© 2026. Italian Society of Medical Radiology.)
Competing Interests: Declarations. Competing interest: The authors have no relevant financial or non-financial interests to disclose. Ethics approval: All procedures adhered to institutional and national ethical standards, in accordance with the 1964 Helsinki Declaration and its subsequent amendments or comparable ethical standards. The study was approved by the ethical committee (Approval Number INT 171/22). Informed consent: Informed consent was obtained from all individual participants involved in the study.
References: Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590. (PMID: 10.3322/caac.2159031912902)
Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101:7–51. https://doi.org/10.1002/cncr.20312. (PMID: 10.1002/cncr.20312)
Sanguinetti A, Polistena A, Lucchini R, Monacelli M, Galasse S, Avenia S, Triola R, Bugiantella W, Cirocchi R, Rondelli F et al (2016) Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our breast unit. Int J Surg Case Rep 20S:8–11. https://doi.org/10.1016/j.ijscr.2016.02.004. (PMID: 10.1016/j.ijscr.2016.02.004269944874883054)
Losurdo A, Rota S, Gullo G, Masci G, Torrisi R, Bottai G, Zuradelli M, Gatzemeier W, Santoro A (2017) Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature. Crit Rev Oncol Hematol 113:283–291. https://doi.org/10.1016/j.critrevonc.2017.03.013. (PMID: 10.1016/j.critrevonc.2017.03.01328427518)
Zheng G, Leone JP (2022) Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment. J Oncol. https://doi.org/10.1155/2022/1734049. (PMID: 10.1155/2022/17340493725155710219774)
Leitlinienprogramm Onkologie Deutsche Krebsgesellschaft (DKG), S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. Accessed 14 November 2020.
Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24:1434–1443. https://doi.org/10.1093/annonc/mdt025. (PMID: 10.1093/annonc/mdt02523425944)
Yu E, Suzuki H, Younus J, Elfiki T, Stitt L, Yau G, Vujovic O, Perera F, Lock M, Tai P (2012) The impact of post-mastectomy radiation therapy on male breast cancer patients–a case series. Int J Radiat Oncol Biol Phys 82:696–700. https://doi.org/10.1016/j.ijrobp.2011.01.010. (PMID: 10.1016/j.ijrobp.2011.01.01021398053)
Jardel P, Vignot S, Cutuli B, Creisson A, Vass S, Barranger E, Thariat J (2018) Should adjuvant radiation therapy be systematically proposed for male breast cancer? Syst Rev Anticancer Res 38:23–31.
Eggemann H, Ignatov A, Stabenow R, von Minckwitz G, Rohl FW, Hass P, Costa SD (2013) Male breast cancer: 20-year survival data for post-mastectomy radiotherapy. Breast Care (Basel) 8:270–275. https://doi.org/10.1159/000354122. (PMID: 10.1159/000354122241320743787884)
Abrams MJ, Koffer PP, Wazer DE, Hepel JT (2017) Postmastectomy radiation therapy is associated with improved survival in node-positive male breast cancer: a population analysis. Int J Radiat Oncol Biol Phys 98:384–391. https://doi.org/10.1016/j.ijrobp.2017.02.007. (PMID: 10.1016/j.ijrobp.2017.02.00728463158)
Colciago RR, Lancellotta V, De Santis MC, Bonzano E, De Rose F, Rocca E, Meduri B, Pasinetti N, Prisco A, Gennari A, Tramm T, Di Cosimo S, Harbeck N, Curigliano G, Poortmans P, Meattini I, Franco P (2024) The role of radiation therapy in the multidisciplinary management of male breast cancer: a systematic review and meta-analysis on behalf of the Clinical Oncology Breast Cancer Group (COBCG). Crit Rev Oncol Hematol 204:104537. https://doi.org/10.1016/j.critrevonc.2024.104537. (PMID: 10.1016/j.critrevonc.2024.10453739454738)
Forster T, Köhler C, El Shafie R, Weykamp F, König L, Arians N, Adeberg S, Michel L, Smetanay K, Golatta M, Sohn C, Heil J, Schneeweiss A, Debus J, Hörner-Rieber J (2020) Adjuvant radiation therapy for male breast cancer-a rare indication? Cancers (Basel) 12(12):3645. https://doi.org/10.3390/cancers12123645. (PMID: 10.3390/cancers12123645332916977761961)
Giuliano AE, Edge SB, Hortobagyi GN (2018) Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol 25(7):1783–1785. https://doi.org/10.1245/s10434-018-6486-6. (PMID: 10.1245/s10434-018-6486-629671136)
Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, Plichta JK, Ricker C, Roshal A, Ruddy KJ, Safer JD, Van Poznak C, Yung RL, Giordano SH (2020) Management of male breast cancer: ASCO guideline. J Clin Oncol 38(16):1849–1863. https://doi.org/10.1200/JCO.19.03120. (PMID: 10.1200/JCO.19.0312032058842)
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346. https://doi.org/10.1016/0360-3016(95)00060-C. (PMID: 10.1016/0360-3016(95)00060-C7713792)
Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8(5):551–561. https://doi.org/10.1002/sim.4780080504. (PMID: 10.1002/sim.47800805042657958)
SAS Documentation. https://documentation.sas.com/doc/en/pgmsascdc/9.4&#95;3.5/grstatproc/p1jayl9r0txttmn1f7duznkpla0a.htm (Last update 14 May 2025).
Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387. https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4%3c361::AID-SIM168%3e3.0.CO;2-4 . (PMID: 8668867). (PMID: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-48668867)
Marubini E, Valsecchi MG. Analysing survival data from clinical trials and Observational Studies;.
Marubini E & Valsecchi MG (1996) Published by John Wiley & Sons 414 pages ISBN 0-971-93987-0 Br J Clin Pharmacol, 41, p. 76.
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509. (PMID: 10.1080/01621459.1999.10474144)
Giordano SH (2018) Breast cancer in men. N Engl J Med. 378(24):2311–2320. https://doi.org/10.1056/NEJMra1707939. (PMID: 10.1056/NEJMra170793929897847)
Wang F, Shu X, Meszoely I, Pal T, Mayer IA, Yu Z, Zheng W, Bailey CE, Shu XO (2019) Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncol 5(11):1589–1596. https://doi.org/10.1001/jamaoncol.2019.2803. (PMID: 10.1001/jamaoncol.2019.2803315361346753503)
National Comprehensive Cancer Network (NCCN) Guidelines. Invasive Breast Cancer. Version 2.2024. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419 . Accessed 3 Jun 2024.
Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Horst K, Moran J, Patton C, Perlmutter J, Warren L, Whelan T, Wright JL, Jagsi R (2018) Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 8(3):145–152. https://doi.org/10.1016/j.prro.2018.01.012. (PMID: 10.1016/j.prro.2018.01.01229545124)
Van den Bruele AB, Williams A, Weiss A (2025) Commentary and updates on the management of male breast cancer. Ann Surg Oncol. https://doi.org/10.1245/s10434-024-16756-x. (PMID: 10.1245/s10434-024-16756-x4098798813383666)
Konduri S, Singh M, Bobustuc G, Rovin R, Kassam A (2020) Epidemiology of male breast cancer. Breast 54:8–14. https://doi.org/10.1016/j.breast.2020.08.010. (PMID: 10.1016/j.breast.2020.08.010328669037476060)
Leone JP, Zwenger AO, Iturbe J, Leone J, Leone BA, Vallejo CT, Bhargava R (2016) Prognostic factors in male breast cancer: a population-based study. Breast Cancer Res Treat 156(3):539–548. https://doi.org/10.1007/s10549-016-3768-1. (PMID: 10.1007/s10549-016-3768-127039306)
Jardel P, Vignot S, Cutuli B, Creisson A, Vass S, Barranger E, Thariat J (2018) Should adjuvant radiation therapy be systematically proposed for male breast cancer? A systematic review. Anticancer Res 38(1):23–31. https://doi.org/10.21873/anticanres.12187 . (PMID: 29277752). (PMID: 10.21873/anticanres.1218729277752)
Lissidini G, Nicosia L, Sargenti M, Cucchi MC, Fabi A, Falco G, Gardani M, Grilz G, Maugeri I, Murgo R, Neri A, Pellini F, Sensi C, Scomersi S, Taffurelli M, Bagnardi V, Oriecuia C, Pagan E, Sangalli C, Dessena M, Veronesi P, Galimberti V (2024) Male breast cancer: a multicenter study to provide a guide for proper management. Breast Cancer Res Treat 208(1):29–40. https://doi.org/10.1007/s10549-024-07380-0. (PMID: 10.1007/s10549-024-07380-038896332)
De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delaloge S, Cortes J, Curigliano G (2022) Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev 109:102434. https://doi.org/10.1016/j.ctrv.2022.102434. (PMID: 10.1016/j.ctrv.2022.10243435933845)
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Consensus Panellist Group (2024) International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol 25(2):e73–e83. https://doi.org/10.1016/S1470-2045(23)00534-X. (PMID: 10.1016/S1470-2045(23)00534-X38301705)
Contributed Indexing: Keywords: Long-term results; Male breast cancer; Overall survival; Radiation therapy
Entry Date(s): Date Created: 20260928 Date Completed: 20261014 Latest Revision: 20261016
Update Code: 20261016
DOI: 10.1007/s11547-026-02276-z
PMID: 42804144
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1826-6983
DOI:10.1007/s11547-026-02276-z